Other Barks & Bites for Friday, April 3: Trump EO Sets 100% Tariffs on Patent Pharmaceutical Imports; Squires Vacates TikTok IPRs Under Tianma Microelectronics; and Kallay Voices DOJ’s Preference for FRAND Obligations

This week in Other Barks & Bites: the Federal Circuit rules that the omission of a co-inventor from a patent invalidates those patent claims if inventorship cannot be corrected; President Donald Trump signs an executive order placing 100% tariffs on drug companies who do not onshore production of patented pharmaceuticals; and more.

Federal Circuit Upholds District Court’s View That Omission of Coinventor Invalidates Patent

In a case of first impression, the U.S. Court of Appeals for the Federal Circuit (CAFC), with Judge Lourie writing, issued a precedential decision today affirming a district court’s grant of summary judgment holding two patents invalid for omitting a coinventor. Fortress Iron LP owns U.S. Patents 9,790,707 (“the ’707 patent”) and 10,883,290, which are both titled “Vertical Cable Rail Barrier.” The final designs for the inventions covered by the two patents were conceived by two Fortress employees and two employees of Fortress’ quality control liaison, Quan Zhou Yoddex Building Material Co., Ltd (YD).

USPTO Life Sciences Listening Session: Remarks of Peter-Anthony Pappas and Henry Hadad

The U.S. Patent and Trademark Office (USPTO) on Monday held the first of three planned Patent Trial and Appeal Board (PTAB)-focused Listening Sessions, this one focused on the PTAB and Life Sciences. Participants in the first panel of the day, who mostly spoke for the branded pharmaceutical industry, discussed the topic of patent thickets and the role of the PTAB in vetting life science patents.

Federal Circuit Affirms PTAB Finding that Centripetal Patent Claims are Unpatentable as Anticipated

The U.S. Court of Appeals for the Federal Circuit (CAFC) issued a decision today in Centripetal Networks, LLC v. Keysight Technologies, Inc., affirming a final written decision of the Patent Trial and Appeal Board (PTAB) and holding that the Board correctly construed a limitation of one independent claim of Centripetal’s patent and properly found that a prior art reference anticipated the claim.

Policymakers Are Falling for a Drug-Pricing Myth

Brand-name drugmakers are manipulating the patent system to block cheap generics from reaching patients. At least, that’s what some lawmakers in Washington have been led to believe. But this narrative, which activist groups have pushed for nearly two decades, unravels under scrutiny. As I demonstrate in a recent study, the data that activists cite as evidence actually undermine their claims.

The USPTO is Trying—But the Most Abusive Practices to Kill Patents Are Still in Play

In modern Patent Trial and Appeal Board (PTAB) practice, aggressive procedural strategy is no longer the exception—it is the operating norm. As the U.S. Patent and Trademark Office (USPTO) has increasingly relied on discretionary denials to constrain inter partes review (IPR), petitioners have adapted. One emerging tactic is the strategic use of ex parte reexamination as a fallback mechanism—deployed either after discretionary denial or, after an unfavorable IPR, or after the petitioner sees the handwriting on the wall and before a final written decision (FWD) is issued in an IPR.

As ‘Pro Codes Act’ is Reintroduced, Opponents Warn of Threats to Standards Development System

Opponents of the “Pro Codes Act” are speaking out this week following its recent reintroduction in the U.S. Senate. The Protecting and Enhancing Public Access to Codes (Pro Codes) Act of 2026, S. 4145, was reintroduced on March 19 by Senators Jon Cornyn, Chris Coons, Mazie Hirono, and Thom Tillis. According to the bill’s sponsors, the legislation “ensures safety standards do not lose copyright protection when they are incorporated into law by name so long as they are accessible for free on a publicly available website.”

Subscribe to IPWatchdog

This is the best way to stay informed. We send a daily roundup of our latest news, press releases, and events.

Get Email Updates